Sanofi has followed in the footsteps of its rivals in the US insulin market with a 78% price cut for its most widely-used Lantus product ... it plans to reduce list prices for its most commonly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback